mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant

Wilfredo F Garcia-Beltran; Kerri J. St Denis; Angelique Hoelzemer; Evan C. Lam; Adam D. Nitido; Maegan L. Sheehan; Cristhian Berrios; Onosereme Ofoman; Christina C. Chang; Blake M. Hauser; Jared Feldman; David J. Gregory; Mark C. Poznansky; Aaron G. Schmidt; A. John Iafrate; Vivek Naranbhai; Alejandro B. Balazs

This article is a Preprint

Preprints are preliminary research reports that have not been certified by peer review. They should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.

Preprints posted online allow authors to receive rapid feedback and the entire scientific community can appraise the work for themselves and respond appropriately. Those comments are posted alongside the preprints for anyone to read them and serve as a post publication assessment.

mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant

Wilfredo F Garcia-Beltran; Kerri J. St Denis; Angelique Hoelzemer; Evan C. Lam; Adam D. Nitido; Maegan L. Sheehan; Cristhian Berrios; Onosereme Ofoman; Christina C. Chang; Blake M. Hauser; Jared Feldman; David J. Gregory; Mark C. Poznansky; Aaron G. Schmidt; A. John Iafrate; Vivek Naranbhai; Alejandro B. Balazs.

Affiliation

Wilfredo F Garcia-Beltran; The Ragon Institute of MGH, MIT, and Harvard
Kerri J. St Denis; The Ragon Institute of MGH, MIT and Harvard
Angelique Hoelzemer; First Department of Internal Medicine, Division of Infectious Diseases, University Medical Centre Eppendorf, Hamburg, Germany
Evan C. Lam; The Ragon Institute of MGH, MIT and Harvard
Adam D. Nitido; The Ragon Institute of MGH, MIT and Harvard
Maegan L. Sheehan; The Ragon Institute of MGH, MIT and Harvard
Cristhian Berrios; Massachusetts General Hospital
Onosereme Ofoman; Massachusetts General Hospital
Christina C. Chang; Center for the AIDS Programme of Research in South Africa, Durban
Blake M. Hauser; The Ragon Institute of MGH, MIT and Harvard
Jared Feldman; The Ragon Institute of MGH, MIT and Harvard
David J. Gregory; Massachusetts General Hospital
Mark C. Poznansky; Massachusetts General Hospital
Aaron G. Schmidt; The Ragon Institute of MGH, MIT and Harvard
A. John Iafrate; Massassachusetts General Hospital
Vivek Naranbhai; Massachusetts General Hospital/ Dana Farber Cancer Institute
Alejandro B. Balazs; The Ragon Institute of MGH, MIT and Harvard

Preprint in En | PREPRINT-MEDRXIV | ID: ppmedrxiv-21267755

Journal article
A scientific journal published article is available and is probably based on this preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See journal article

ABSTRACT

ABSTRACT

Recent surveillance has revealed the emergence of the SARS-CoV-2 Omicron variant (BA.1/B.1.1.529) harboring up to 36 mutations in spike protein, the target of vaccine-induced neutralizing antibodies. Given its potential to escape vaccine-induced humoral immunity, we measured neutralization potency of sera from 88 mRNA-1273, 111 BNT162b, and 40 Ad26.COV2.S vaccine recipients against wild type, Delta, and Omicron SARS-CoV-2 pseudoviruses. We included individuals that were vaccinated recently (<3 months), distantly (6-12 months), or recently boosted, and accounted for prior SARS-CoV-2 infection. Remarkably, neutralization of Omicron was undetectable in most vaccinated individuals. However, individuals boosted with mRNA vaccines exhibited potent neutralization of Omicron only 4-6-fold lower than wild type, suggesting that boosters enhance the cross-reactivity of neutralizing antibody responses. In addition, we find Omicron pseudovirus is more infectious than any other variant tested. Overall, this study highlights the importance of boosters to broaden neutralizing antibody responses against highly divergent SARS-CoV-2 variants.

License

cc_by_nc

Fulltext

Add to My VHL

XML

Search on Google

Full text: 1 Collection: 09-preprints Database: PREPRINT-MEDRXIV Type of study: Rct Language: En Year: 2021 Document type: Preprint

Fulltext

Add to My VHL

XML

Search on Google

Full text: 1 Collection: 09-preprints Database: PREPRINT-MEDRXIV Type of study: Rct Language: En Year: 2021 Document type: Preprint